المؤلفون: Merle, Philippe, Kudo, Masatoshi, Edeline, Julien, Bouattour, Mohamed, Cheng, Ann-Lii, Chan, Stephen, Yau, Thomas, Garrido, Marcelo, Knox, Jennifer, Daniele, Bruno, Breder, Valeriy, Lim, Ho Yeong, Ogasawara, Sadahisa, Cattan, Stéphane, Chao, Yee, B. Siegel, Abby, Martinez-Forero, Iván, Wei, Ziwen, Liu, C, Finn, Richard

المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Kindai University, Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), National Taïwan University (NTU), The Chinese University of Hong Kong Hong Kong (CUHK), The University of Hong Kong (HKU), Pontificia Universidad Católica de Chile (UC), University of Toronto, N.N. Blokhin National Medical Research Center of Oncology, Sungkyunkwan University Suwon (SKKU), Chiba University, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Pharmaceutical Sciences, Merck & Co. Inc., Merck Research laboratories, Merck Sharp and Dohme (Merck & Co. Inc)-Merck Sharp and Dohme (Merck & Co. Inc), University of California Los Angeles (UCLA), University of California (UC)

المصدر: ISSN: 2235-1795.

مصطلحات موضوعية: Pembrolizumab, Medicine, Placebo, Sorafenib, Internal medicine, Clinical endpoint, Randomization, Gastroenterology, Hepatocellular carcinoma, Randomized controlled trial, Oncology, Cancer, Immunotherapy, Pathology, Alternative medicine, [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37901200; hal-04265920; https://hal.science/hal-04265920Test; https://hal.science/hal-04265920/documentTest; https://hal.science/hal-04265920/file/000529636.pdfTest; PUBMED: 37901200

الإتاحة: https://doi.org/10.1159/000529636Test
https://hal.science/hal-04265920Test
https://hal.science/hal-04265920/documentTest
https://hal.science/hal-04265920/file/000529636.pdfTest

المؤلفون: Chouik, Yasmina, Erard, Domitille, Demian, Hassan, Schulz, Thomas, Mazard, Tessa, Hartig-Lavie, Kerstin, Antonini, Teresa, Mabrut, Jean‐yves, Mohkam, Kayvan, Rode, Agnès, Merle, Philippe

المساهمون: Service d'Hépatologie Hôpital de la Croix-Rousse - HCL, Hôpital de la Croix-Rousse CHU - HCL, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL)

المصدر: ISSN: 1664-3224.

مصطلحات موضوعية: immunotherapy, case-report, liver transplantation, Atezolizumab, complete response, Bevacizumab, hepatocellular carcinoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

العلاقة: hal-04161261; https://hal.science/hal-04161261Test; https://hal.science/hal-04161261/documentTest; https://hal.science/hal-04161261/file/fimmu-14-1205997.pdfTest

الإتاحة: https://doi.org/10.3389/fimmu.2023.1205997Test
https://hal.science/hal-04161261Test
https://hal.science/hal-04161261/documentTest
https://hal.science/hal-04161261/file/fimmu-14-1205997.pdfTest

المؤلفون: Nguyen-Khac, Eric, Nahon, Pierre, Ganry, Olivier, Ben Khadhra, Hajer, Merle, Philippe, Amaddeo, Giuliana, Ganne-Carrie, Nathalie, Silvain, Christine, Peron, Jean-Marie, Mathurin, Philippe, Anty, Rodolphe, Uguen, Thomas, Decaens, Thomas, Riachi, Ghassan, Bouattour, Mohamed, Baron, Aurore, Bronowicki, Jean-Pierre, Pageaux, Georges-Philippe, Rosmorduc, Olivier, Ducournau, Gérard, Gilberg, Mélinda, Tanang, Alexandre, Dupin, Julien, Gilbert-Marceau, Anika, Blanc, Jean-Frédéric

المساهمون: Université de Lille, Inserm, CHU Lille, CHU Amiens-Picardie, Université Sorbonne Paris Cité USPC, Hospices Civils de Lyon HCL, Hôpital Henri Mondor, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU de Poitiers, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, Centre Hospitalier Régional Universitaire CHU Lille CHRU Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Université Côte d'Azur UniCA, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, CHU Rouen, Hôpital Beaujon AP-HP, Centre Hospitalier Sud Francilien, Centre Hospitalier Universitaire de Nancy CHU Nancy, CHU Montpellier, Hôpital Paul Brousse, Roche France, CHU Bordeaux

مصطلحات موضوعية: epidemiology, immunotherapy, liver cancer, real-world evidence, targeted therapy

العلاقة: European Journal of Gastroenterology & Hepatology; Eur J Gastroenterol Hepatol; http://hdl.handle.net/20.500.12210/105975Test

الإتاحة: https://doi.org/20.500.12210/105975Test
https://hdl.handle.net/20.500.12210/105975Test

المؤلفون: Ren, Zhenggang, Ducreux, Michel, Abou-Alfa, Ghassan K, Merle, Philippe, Fang, Weijia, Edeline, Julien, Li, Zhiwei, Wu, Lihua, Assenat, Eric, Hu, Sheng, Rimassa, Lorenza, Zhang, Tao, Blanc, Jean-Frederic, Pan, Hongming, Ross, Paul, Yen, Chia-Jui, Tran, Albert, Shao, Guoliang, Bouattour, Mohamed, Chen, Yajin, Meyer, Tim, Hou, Jinlin, Tougeron, David, Bai, Yuxian, Hou, Ming-Mo, Meng, Zhiqiang, Wu, John, Li, Vincent, Chica-Duque, Sandra, Cheng, Ann-Lii

المصدر: Liver Cancer (2022) (In press).

مصطلحات موضوعية: Tislelizumab, Hepatocellular carcinoma, Immunotherapy, Pretreated patient population

وصف الملف: application/pdf

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10161827/1/527175.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10161827Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10161827/1/527175.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10161827Test/

المؤلفون: Roth, Gael S., Villeret, François, Decaens, Thomas, Merle, Philippe, Nahon, Pierre

المصدر: Liver International; Mar2023, Vol. 43 Issue 3, p546-557, 12p, 1 Diagram, 2 Charts

مصطلحات موضوعية: LIVER diseases, HEPATOCELLULAR carcinoma, CLINICAL trials, ETIOLOGY of diseases, IMMUNOTHERAPY

المؤلفون: Ren, Zhenggang, Ducreux, Michel, Abou-Alfa, Ghassan K., Merle, Philippe, Fang, Weijia, Edeline, Julien, Li, Zhiwei, Wu, Lihua, Assenat, Eric, Hu, Sheng, Rimassa, Lorenza, Zhang, Tao, Blanc, Jean-Frédéric, Pan, Hongming, Ross, Paul, Yen, Chia-Jui, Tran, Albert, Shao, Guoliang, Bouattour, Mohamed, Chen, Yajin

المصدر: Liver Cancer (2235-1795); 2023, Vol. 12 Issue 1, p72-84, 13p

مصطلحات موضوعية: HEPATOCELLULAR carcinoma, ADVERSE health care events, TERMINATION of treatment, LIVER cancer

المؤلفون: Ryoo, Baek‐Yeol¹ (AUTHOR), Merle, Philippe² (AUTHOR), Kulkarni, Amit S.³ (AUTHOR), Cheng, Ann‐Lii⁴ (AUTHOR), Bouattour, Mohamed⁵ (AUTHOR), Lim, Ho Yeong⁶ (AUTHOR), Breder, Valeriy⁷ (AUTHOR), Edeline, Julien⁸ (AUTHOR), Chao, Yee⁹ (AUTHOR), Ogasawara, Sadahisa¹⁰ (AUTHOR), Yau, Thomas¹¹ (AUTHOR), Garrido, Marcelo¹² (AUTHOR), Chan, Stephen L.¹³ (AUTHOR), Daniele, Bruno¹⁴ (AUTHOR), Norquist, Josephine M.³ (AUTHOR), Chen, Erluo³ (AUTHOR), Siegel, Abby B.³ (AUTHOR), Zhu, Andrew X.^15,16 (AUTHOR), Finn, Richard S.¹⁷ (AUTHOR), Kudo, Masatoshi¹⁸ (AUTHOR) m-kudo@med.kindai.ac.jp

المصدر: Cancer (0008543X). Mar2021, Vol. 127 Issue 6, p865-874. 10p.

مصطلحات موضوعية: *DRUG efficacy, *PEMBROLIZUMAB, *QUALITY of life, *SORAFENIB

المؤلفون: Merle, Philippe^1,2,3,4 philippe.merle@inserm.fr

المصدر: Hépato-Gastro & Oncologie Digestive. Supplement 1, Vol. 27, p35-40. 6p.

المؤلفون: Merle, Philippe¹ (AUTHOR) philippe.merle@inserm.fr

المصدر: Cancers. Jan2021, Vol. 13 Issue 2, p238-238. 1p.

مصطلحات موضوعية: *THERAPEUTIC use of antineoplastic agents, *ANTINEOPLASTIC agents, *CANCER relapse, *COMBINED modality therapy, *DRUG efficacy, *HEPATOCELLULAR carcinoma, *IMMUNOTHERAPY, *PATIENT safety, *SURVIVAL, *TUMOR markers, *PROTEIN-tyrosine kinase inhibitors, *TREATMENT effectiveness, *DISEASE progression, *IMMUNE checkpoint inhibitors, *THERAPEUTICS